Company: DTCK
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001683168-25-001820
Chunk: 2

Company: DAVIS COMMODITIES Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 2
---
us provides a general description
of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings.
The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus.
You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any
documents incorporated by reference, before you invest in any of the securities being offered.

This prospectus may not be used to sell our securities
unless accompanied by a prospectus supplement. The prospectus supplement or any related free writing prospectus may also add to, update,
supplement or clarify information contained in this prospectus.

Pursuant to General Instruction I.B.5. of Form
F-3, in no event will we sell the securities covered hereby in a public primary offering with a value exceeding more than one-third of
the aggregate market value of our Ordinary Shares in any 12-month period so long as the aggregate market value of our outstanding Ordinary
Shares held by non-affiliates remains below $75,000,000.

The aggregate market value of our outstanding
voting and non-voting common equity held by non-affiliates is approximately $7,346,792.48 based on the closing price of $0.92 per ordinary
share on March 21, 2025 and 7,985,644 ordinary shares held by non-affiliates. During the 12 calendar months prior to and including the
date of this prospectus, we have not offered or sold any securities pursuant to General Instruction I.B.5 of Form F-3.

Our Ordinary Shares are listed on the Nasdaq Capital
Market under the symbol “DTCK.” The applicable prospectus supplement will contain information, where applicable, as to other
listings, if any, on the Nasdaq Capital Market or other securities exchange of the securities covered by the prospectus supplement.

Investing in our securities involves a high degree of risk. Before making an investment decision, please read the information under the heading “ Risk Factors” beginning on page 7 of this prospectus and risk factors set forth in our most recent annual report on Form 20-F (the “2023 Annual Report”), in other reports incorporated herein by reference, and in an applicable prospectus supplement under the heading “